Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Perspectives on Kidney Cancer

Posted by Matt Breese on Dec 19, 2017

Find me on:

new-blog-image-class.png

There has been an increasing prevalence of kidney cancer during the past decade. Several pharma manufacturers are stepping up to the plate with promising treatment options. Through 2024, the global market for kidney cancer drugs is expected to continue to grow. 
 
According to an analysis conducted by Grand View Research"The Asia-Pacific market is estimated to witness the fastest growth rate for the kidney cancer drugs market."
 

In the US, another potential treatment option could be on the horizon. According to a recent report from FiercePharma:

"Bristol-Myers Squibb could have yet another approval for its Opdivo-plus-Yervoy combo on the way. The FDA has started a priority review on the two-drug combo as a treatment for kidney cancer, based on data released just three months ago.The combination regimen, which pairs Bristol's PD-1 immunotherapy Opdivo with its CTLA4 drug Yervoy, is up for an approval for intermediate- and poor-risk patients with advanced renal cell carcinoma, and the FDA is due to decide next April."

In coming years, the kidney cancer drug pipeline will continue to have a flow of new drugs entering the market. It will be crucial to keep a close eye on the market access in this class.  

Subscribe to the MMIT blog for more pharma, provider, and payer perspectives on key topics that affect the healthcare network.

Subscribe for Weekly Perspectives

Topics: Specialty, Market Access